Fusion Antibodies – emphasises second half improvement… why a muted share price response?
By Steve Moore | Thursday 18 April 2019
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
“Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract research organisation specialising in antibody engineering services, provides a business and unaudited trading update for year ended 31 March 2019, confirming the improvement in second half performance announced on 25 February 2019”. Sounds positive – though despite being down from more than 100p in August and even a start of 2019 more than 50p, the shares nudging up to only 30p?...
You must be a registered member to read this story
ShareProphets is reader-supported journalism
Join us for free and gain access to three articles per month
Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.